Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF
Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF Summary
Accession # XP_005578557
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
B7-H6 is a 55 kDa glycosylated member of the B7 family of immune costimulatory proteins (1, 2). Mature B7-H6 consists of an extracellular domain (ECD) that with one Ig-like V domain and one Ig-like C1 domain, a transmembrane segment, and a cytoplasmic domain that contains one ITIM, one SH2, and one SH3 motif (3). Both of the Ig-like domains carry N-linked glycosylation (4). Within the ECD, cynomolgous B7-H6 shares 81%, 81%, 77% and 80% amino acid sequence identity with chimpanzee, orangutan, gibbon, and human B7-H6, respectively. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells (4, 5). It does not show binding to NKp44, NKp46, or NKG2D (3, 6). Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis (3). B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors (3, 7). B7-H6 is up-regulated on inflammatory monocytes and neutrophils, and a 30 kDa soluble fragment can be released by ADAM-10 or ADAM-17 mediated shedding (8, 9). The expression of B7-H6 on tumor cells correlates with cancer progression and patient's survival in human ovarian cancer (10).
- Zou, W. and L. Chen (2008) Nat. Rev. Immunol. 8:467.
- Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
- Brandt, C.S. et al. (2009) J. Exp. Med. 206:1495.
- Li, Y. et al. (2011) J. Exp. Med. 208:703.
- Joyce, M.G. et al. (2011) Proc. Natl. Acad. Sci. USA 108:6223.
- Arnon, T.I. et al. (2006) Semin. Cancer Biol. 16:348.
- Byrd, A. et al. (2007) PLoS ONE 2:e1339.
- Matta, J. et al. (2013) Blood 122:394.
- Schlecker, E. et al. (2014) Cancer Res. 74:3429.
- Zhou, Y. et al. (2015) Int. J. Clin. Exp. Pathol. 8:9428.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image